IRIS
BARGAGLI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 16.047
NA - Nord America 13.231
AS - Asia 2.386
AF - Africa 111
SA - Sud America 36
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 9
Totale 31.853
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.111
IT - Italia 3.878
GB - Regno Unito 3.300
IE - Irlanda 2.997
SE - Svezia 1.320
RU - Federazione Russa 1.270
CN - Cina 1.120
FR - Francia 820
UA - Ucraina 756
DE - Germania 722
SG - Singapore 642
FI - Finlandia 466
VN - Vietnam 186
ES - Italia 170
IN - India 122
CA - Canada 109
CZ - Repubblica Ceca 98
CI - Costa d'Avorio 87
HK - Hong Kong 54
TR - Turchia 50
BE - Belgio 41
IR - Iran 38
NL - Olanda 38
AU - Australia 29
JP - Giappone 27
PL - Polonia 26
KR - Corea 23
AT - Austria 20
PH - Filippine 20
PT - Portogallo 20
CH - Svizzera 16
PK - Pakistan 15
DK - Danimarca 12
RO - Romania 11
BG - Bulgaria 10
BR - Brasile 10
EU - Europa 9
GR - Grecia 9
AZ - Azerbaigian 8
KZ - Kazakistan 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
LK - Sri Lanka 7
LV - Lettonia 7
MK - Macedonia 7
NG - Nigeria 7
SA - Arabia Saudita 7
BD - Bangladesh 6
KG - Kirghizistan 6
LT - Lituania 6
EE - Estonia 5
EG - Egitto 5
ID - Indonesia 5
IL - Israele 5
LA - Repubblica Popolare Democratica del Laos 5
MA - Marocco 5
MX - Messico 5
AR - Argentina 4
GE - Georgia 4
NZ - Nuova Zelanda 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
AL - Albania 3
CY - Cipro 3
EC - Ecuador 3
HU - Ungheria 3
IS - Islanda 3
JM - Giamaica 3
JO - Giordania 3
LU - Lussemburgo 3
RS - Serbia 3
AM - Armenia 2
BO - Bolivia 2
BY - Bielorussia 2
CO - Colombia 2
PA - Panama 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
BH - Bahrain 1
CR - Costa Rica 1
DZ - Algeria 1
HR - Croazia 1
KH - Cambogia 1
KW - Kuwait 1
MM - Myanmar 1
MY - Malesia 1
NO - Norvegia 1
SC - Seychelles 1
SI - Slovenia 1
TN - Tunisia 1
Totale 31.853
Salva come PNG Salva come JPEG
Città #
Southend 3.037
Dublin 2.958
Fairfield 2.071
Chandler 1.436
Ashburn 1.156
Woodbridge 879
Siena 797
Seattle 738
Houston 726
Wilmington 694
Cambridge 629
Jacksonville 579
Singapore 496
Princeton 475
Ann Arbor 405
Lastra a Signa 349
Helsinki 341
Beijing 262
New York 232
Florence 223
Dong Ket 184
Nanjing 177
Boardman 150
San Diego 150
Dearborn 138
Milan 138
Munich 136
Shanghai 134
Moscow 130
Rome 129
San Mateo 127
Málaga 121
Fremont 100
Abidjan 87
London 87
Nanchang 73
Brno 67
Menlo Park 55
Shenyang 50
Washington 49
Los Angeles 44
Ottawa 43
Dallas 41
Gavirate 41
Brussels 40
Norwalk 39
Catania 37
Izmir 36
Guangzhou 34
Hebei 33
Hong Kong 32
Redwood City 32
Hangzhou 31
Naples 30
Changsha 29
Chicago 29
Lappeenranta 29
Kunming 28
Olomouc 28
Jinan 26
San Francisco 26
Tarazona 26
Tianjin 26
Jiaxing 25
Santa Clara 25
Toronto 25
Livorno 22
Agliana 21
Vienna 20
Zhengzhou 20
Gießen 19
Düsseldorf 18
Nuremberg 18
Padova 18
Bologna 16
Frankfurt am Main 16
Prato 16
Zanjan 16
Hefei 15
Paris 15
Seongnam 15
Venezia 15
Arezzo 14
Lancaster 14
Ningbo 14
Chianciano Terme 13
Hyderabad 13
Newark 13
Pisa 13
Amsterdam 12
Bangalore 12
Brescia 12
Central 12
Genoa 12
Grosseto 12
Phoenix 12
Warsaw 12
Aachen 11
Kilburn 11
Bergamo 10
Totale 22.102
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 958
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 308
Cytokine modulators in the treatment of sarcoidosis 233
Gorham-Stout disease management during pregnancy 202
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 200
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 199
Genetic mechanisms of critical illness in COVID-19 199
Antirheumatic agents in covid-19: is IL-6 the right target? 198
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 195
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 194
Peripheral biomarkers' panel for severe COVID-19 patients 192
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 189
Exhaled nitric oxide in interstitial lung diseases 188
A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls 186
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 185
Increased Risk of Atherosclerosis in Patients with Sarcoidosis 183
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 182
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 181
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 181
Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity 179
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 176
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 174
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 173
Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress 168
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 166
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 166
Combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF): A novel disease phenotype? 166
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 166
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 165
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 163
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 163
Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline 160
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 158
Quality of life, anxiety and depression in Sarcoidosis 157
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 155
Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases 154
NK and NKT-like cells in granulomatous and fibrotic lung diseases 152
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 152
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 152
Phenotypes of organ involvement in sarcoidosis 152
Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways 152
Serum analysis of coagulation factors in IPF and NSIP 150
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 150
The analysis of tryptase in serum of sarcoidosis patients 147
Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia 147
Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer 146
Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension 146
null 145
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 145
Sarcoidosis: a review for the internist 145
null 143
Oxidative stress in the pathogenesis of diffuse lung diseases: a review 142
Fibrotic Lung Toxicity Induced by Hydroxycarbamide 142
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 142
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 142
Chromosome 5 inversion in two siblings, one with Klinefelter syndrome and systemic sclerosis, the other with rheumatoid arthritis 141
Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. 140
Sarcoidosis with upper respiratory tract involvement 139
Prognostic bioindicators in severe COVID-19 patients 139
Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 138
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 138
Carbonylated proteins in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis 137
Research highlights from the 2018 ERS International Congress: interstitial lung diseases 137
Serum amyloid A in patients with idiopathic pulmonary fibrosis 137
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 137
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre 136
Extracorporeal Photopheresis in Lung Transplantation 136
Atypical HRCT manifestations of pulmonary sarcoidosis 135
Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis 134
Analysis of trace elements in bronchoalveolar lavage of patients with diffuse lung diseases 134
Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with interstitial lung diseases. 133
Calgranulin B (S100A9/MRP14): a Key molecule in idiopathic pulmonary fibrosis? 133
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 132
Pathogen-sugar interactions revealed by universal saturation transfer analysis 131
A genome-wide association study reveals evidence of association with sarcoidosis at 6p12.1 130
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 130
Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small cell lung cancer: anlysis of risk factors. 129
Proteomic investigation of pulmonary sarcoidosis 128
Controversial role of RAGE in the pathogenesis of idiopathic pulmonary fibrosis 128
Assessment of cardiac involvement in sarcoidosis by echocardiography 126
Human Chitotriosidase: a sensitive biomarker of sarcoidosis 125
Serial KL-6 measurements in COVID-19 patients 125
Mapping the human genetic architecture of COVID-19 125
Omalizumab treatment in Samter's triad: case series and review of the literature 124
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 124
Proteome analysis of bronchoalveolar lavage in lung diseases 123
SARS-CoV-2 in pleural fluid in a kidney transplant patient 123
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 123
Concentrations of major elements and mercury in unstimulated human saliva 122
Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis 122
Idiopathic pulmonary fibrosis [Fibrosi polmonare idiopatica] 121
null 121
Immunoglobulin replacement therapy for yellow nail syndrome 121
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 121
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 121
Gardening in greenhouses as a risk factor for silicosis. 120
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 119
Serum chitotriosidase activity in sarcoidosis patients 118
Proteome analysis of bronchoalveolar lavage in pulmonary langerhans cell histiocytosis 118
M2 marker expression by alveolar macrophages predicts survival in IPF 118
Totale 15.946
Salva come PNG Salva come JPEG
Categoria #
all - tutte 129.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.822 0 0 0 0 311 373 378 517 371 381 160 331
2020/20215.455 198 503 235 694 365 656 317 663 496 375 422 531
2021/20224.509 351 594 368 307 224 157 199 211 186 526 485 901
2022/20235.759 426 595 721 693 420 1.048 359 491 450 203 213 140
2023/20245.542 218 138 518 273 294 1.285 1.652 226 62 180 179 517
2024/20253.582 715 525 1.293 672 377 0 0 0 0 0 0 0
Totale 33.117